Ligand Pharmaceuticals Incorporated (LGND) exhibits 45.0% gross margins and 3.0% return on invested capital within Health Care (Biotechnology: Pharmaceutical Preparations), balanced against a 95.0x enterprise multiple and 4.8% implied options volatility.
Sustained 45.0% gross profitability converts into 15.3% operating margin and 3.0% ROIC, outpacing sector cost of capital.
ROIC: 3.0% // GM: 45.0%YoY revenue trajectory of +60.4% paired with 0.77% free cash flow yield supports self-funded R&D and capital return.
REV YOY: +60.4% // FCF YLD: 0.77%Altman Z-Score of 8.40 and Piotroski F-Score of 8/9 indicate low near-term refinancing stress.
ALTMAN Z: 8.40 // F-SCORE: 8/9Trading at 50.8x trailing P/E (42.7x Fwd P/E) leaves valuation vulnerable if real 10Y TIPS yields spike.
P/E: 50.8x // EV/EBITDA: 95.0xOptions market prices a ±5.2% implied move with a 0.85 put/call ratio around $307.02 max pain.
IMPL MOVE: ±5.2% // P/C: 0.85Elevated industry capital intensity and customer concentration in Biotechnology: Pharmaceutical Preparations require continuous execution to defend 46.4% net margins.
NET MARGIN: 46.4% // D/E: 0.22x| FILER | SIDE | $ VALUE |
|---|---|---|
| INSPECT FULL OWNERSHIP LEDGER IN OWN <GO> | ||
| STRIKE / EXP | TYPE | PREMIUM |
|---|---|---|
| INSPECT GEX & CHAIN IN OPT <GO> | ||
Unblur the exact $50,000 delta-adjusted ETF/options hedge ratio for LGND & activate live FRED threshold breach alerts.